Partners using AI and machine learning for drug discovery Business Weekly Technology News Business news

LifeArc, the UK-based medical research charity, and the Milner Therapeutics Institute at Cambridge University have formed an alliance to use artificial intelligence and machine learning to identify and validate new drug targets in immuno-oncology and respiratory diseases. Cutting-edge machine learning approaches will be developed, validated and integrated into drug discovery processes to identify novel therapeutic targets, stratify patient populations and predict efficacy of new and existing drugs. Data generated will enhance the design of key experiments to validate and prioritise targets. Scientists involved in the project will be co-located at LifeArc and Milner Therapeutics to take full advantage of both environments. Professor Tony Kouzarides (pictured), director of the Milner Therapeutics Institute said: "We are delighted to be working closely with LifeArc in applying artificial intelligence and machine learning approaches to drug discovery. "There is a lot of interest in these methods for the potential to benefit patients.